SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

LF von Weikersthal; PJ Goebell; M de Santis; C Lerchenmuller; U Zimmermann; MMEM Bos; W Freier; S Schirrmacher-Memmel; M Staehler; Sascha Pahernik; M Los; M Schenck; A Floercken; C van Arkel; K Hauswald; M Indorf; D Gottstein; C Eichelberg; MS Michel

SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

LF von Weikersthal, PJ Goebell, M de Santis, C Lerchenmuller, U Zimmermann, MMEM Bos, W Freier, S Schirrmacher-Memmel, M Staehler, Sascha Pahernik, M Los, M Schenck, A Floercken, C van Arkel, K Hauswald, M Indorf, D Gottstein, C Eichelberg, MS Michel

Department of Urology

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	5-5
Journal	Oncology Research and Treatment
Volume	37
Publication status	Published - 2014

Cite this

von Weikersthal, LF., Goebell, PJ., de Santis, M., Lerchenmuller, C., Zimmermann, U., Bos, MMEM., Freier, W., Schirrmacher-Memmel, S., Staehler, M., Pahernik, S., Los, M., Schenck, M., Floercken, A., van Arkel, C., Hauswald, K., Indorf, M., Gottstein, D., Eichelberg, C., & Michel, MS. (2014). SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Oncology Research and Treatment, 37, 5-5.

@article{e6094d8562434a0a87fdfe0a73af4781,

title = "SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)",

author = "{von Weikersthal}, LF and PJ Goebell and {de Santis}, M and C Lerchenmuller and U Zimmermann and MMEM Bos and W Freier and S Schirrmacher-Memmel and M Staehler and Sascha Pahernik and M Los and M Schenck and A Floercken and {van Arkel}, C and K Hauswald and M Indorf and D Gottstein and C Eichelberg and MS Michel",

year = "2014",

language = "English",

volume = "37",

pages = "5--5",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

}

von Weikersthal, LF, Goebell, PJ, de Santis, M, Lerchenmuller, C, Zimmermann, U, Bos, MMEM, Freier, W, Schirrmacher-Memmel, S, Staehler, M, Pahernik, S, Los, M, Schenck, M, Floercken, A, van Arkel, C, Hauswald, K, Indorf, M, Gottstein, D, Eichelberg, C & Michel, MS 2014, 'SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)', Oncology Research and Treatment, vol. 37, pp. 5-5.

SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). / von Weikersthal, LF; Goebell, PJ; de Santis, M et al.
In: Oncology Research and Treatment, Vol. 37, 2014, p. 5-5.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

AU - von Weikersthal, LF

AU - Goebell, PJ

AU - de Santis, M

AU - Lerchenmuller, C

AU - Zimmermann, U

AU - Bos, MMEM

AU - Freier, W

AU - Schirrmacher-Memmel, S

AU - Staehler, M

AU - Pahernik, Sascha

AU - Los, M

AU - Schenck, M

AU - Floercken, A

AU - van Arkel, C

AU - Hauswald, K

AU - Indorf, M

AU - Gottstein, D

AU - Eichelberg, C

AU - Michel, MS

PY - 2014

Y1 - 2014

M3 - Abstract (Journal)

SN - 2296-5270

VL - 37

SP - 5

EP - 5

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -